ObjectivesIn patients with rheumatoid arthritis (RA), high disease activity impairs fertility outcomes and increases the risk of adverse pregnancy outcomes. The aim of this study was to determine the feasibility of a modern treatment approach, including treat-to-target (T2T) and the prescription of tumour necrosis factor (TNF) inhibitors, in patients with RA with a wish to conceive or who are pregnant.MethodsPatients were derived from the Preconception Counseling in Active RA (PreCARA) cohort. Patients with a wish to conceive or who are pregnant were treated according to a modified T2T approach, in which the obvious restrictions of pregnancy were taken into account. Results of the PreCARA study were compared with results of the Pregnancy-induced Amelioration of Rheumatoid Arthritis (PARA) study, a historic reference cohort on RA during pregnancy. Patients in the PARA cohort were treated according to the standards of that time (2002–2010). Differences in disease activity over time between the two cohorts were tested using a linear mixed model.Results309 patients with RA were included in the PreCARA study, 188 children were born. 47.3% of the patients used a TNF inhibitor at any time during pregnancy. Mean disease activity over time in the PreCARA cohort was lower than in the reference cohort (p<0.001). In the PreCARA cohort, 75.4% of the patients were in low disease activity (LDA) or remission before pregnancy increasing to 90.4% in the third trimester, whereas in the PARA cohort, these percentages were 33.2% and 47.3%, respectively.ConclusionsThis first study on a modern treatment approach in pregnant patients with RA shows that LDA and remission are an attainable goal during pregnancy, with 90.4% of patients achieving this in the third trimester.
Background:A treat-to-target approach results in better outcomes for Rheumatoid Arthritis (RA) patients [1]. Well controlled disease is important for pregnant RA patients and patients with a wish to conceive too. Not only for the welfare of the mother, but also because active disease is associated with a prolonged time to pregnancy and adverse pregnancy outcomes [2]. This is this first study to examine a treat-to-target approach during pregnancy.Objectives:To determine the feasibility of a treat-to-target approach in RA patients with a wish to conceive or pregnant.Methods:Patients were derived from the PreCARA cohort (first inclusion 2011, data shown up to November 2019). The PreCARA cohort is an ongoing, single center, prospective study on RA and pregnancy. Patients in this cohort were treated according to a treat-to-target approach, in which the obvious restrictions of pregnancy were taken into account. Study visits were scheduled before, during and after pregnancy and disease activity (DAS28CRP) was measured. Results of the PreCARA study were compared with results of the PARA study [3], a historic reference cohort on RA during pregnancy, with a similar study design (inclusion 2002 – 2010). Patients in the PARA cohort were treated according to the standards of that time. The PARA cohort represents the natural course of RA during pregnancy with limited treatment options.Results:263 RA patients were included in the PreCARA cohort, up to now 154 children were born in this ongoing cohort. Mean age at inclusion was 32.3 (4.3 SD), 83.2 % was Rheumatoid Factor positive and/or ACPA positive. Mean disease activity in the PreCARA cohort is statistically significant lower than in the PARA cohort at every time-point: mean DAS28CRP in 3rdtrimester in the PreCARA cohort 2.22 (0.73 SD), in the PARA cohort 3.35 (1.12 SD) P < 0.001 (figure 1). In the PreCARA cohort 73.3% of the patients were in low disease activity or remission before pregnancy increasing to 90.4 % in the third trimester, whereas in the PARA cohort these percentages were 32.2 % and 47.3% respectively (P < 0.001) (figure 2). Medication use in the PreCARA cohort is shown in table 1 and in the PARA cohort in table 2.MedicationBefore pregnancy (%)*1sttrimester (%)2ndtrimester (%)3rdtrimester (%)6 weeks post-partum (%)12 weeks post-partum (%)26 weeks post-partum (%)MTX5000151915Leflunomide0000112Abatacept0000111Hydroxychloroqine63515150494331Sulfasalazine70565857544736Prednisone43403942383427Azathioprine1211011Certolizumab25212628262418Adalimumab10500334Infliximab5830111Etanercept13109310119Golimumab0000001Tocilizumab3100323* patients seen before pregnancy = 104MedicationBefore pregnancy (%)**1sttrimester (%)2ndtrimester (%)3rdtrimester (%)6 weeks post-partum (%)12 weeks post-partum (%)26 weeks post-partum (%)MTX0000183036Leflunomide0000012Hydroxychloroqine6222487Sulfasalazine34252726263029Prednisone42333636353632Azathioprine1000111Adalimumab0000235Infliximab0000011Etanercept0000365** patients seen before pregnancy = 124Conclusion:This first study on a treat-to-target approach in pregnant RA patients shows that low disease activity and remission are an attainable goal during pregnancy, with over 90% of patients achieving this in the 3rdtrimester. The effect of this approach on fertility and pregnancy outcomes should be the focus of further studies.References:[1]Smolen et al. Rheumatoid arthritis. Lancet 2016[2]Smeele et al. Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis. Semin Arthritis Rheum 2019[3]de Man et al. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. A&R 2007Disclosure of Interests:Hieronymus TW Smeele: None declared, Esther Röder: None declared, Hetty Wintjes: None declared, Laura JC Kranenburg - van Koppen: None declared, Johanna Hazes: None declared, Radboud Dolhain Grant/research support from: unrestricted grant from UCB Pharma
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.